• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Fluoxetine or Venlafaxine for Early Post Stroke Depression
Conclusions: PSD in the early phase affects a substantial number of the stroke patients. Venlafaxine has got a better outcome and adverse event profile compared to fluoxetine in this group of patients. However, larger multicenter studies will provide more helpful data in this area.
Source: Neurology India - December 19, 2022 Category: Neurology Authors: Vivek K Nambiar J Parvathy Tania M Philip K Abhijith S Sreeni Naveen K Panicker Amrutha V Ajai TS Dhanya Source Type: research

Should This Patient With Ischemic Stroke Receive Fluoxetine?
You admit T.R., a 75-year-old man, to your inpatient rehabilitation unit 10 days after a stroke. He has a medical history of hypertension and type II diabetes. On the day of his admission to the neurology service, he experienced a sudden onset of severe left-sided weakness with a facial droop and slurring of speech. His husband was driving them both to a social event at the time and detoured immediately to the emergency department, where the patient received tissue plasminogen activator (tPA) for a large, right middle cerebral artery thrombosis seen on magnetic resonance imaging.
Source: PM and R - December 1, 2015 Category: Rehabilitation Authors: Heidi Schambra, Brian Im, Michael W. O'Dell Tags: Point/Counterpoint Source Type: research

Role of TREK-1 in Health and Disease, Focus on the Central Nervous System
Conclusion and Perspectives Since their cloning 20 years ago, the physiological importance of TREK-1 channels has continued to grow (Figure 3). Today, TREK-1 channels have been shown to be important and their presence is essential in a number of physiopathological processes. Their involvement in these different processes demonstrate the necessity to design pharmacological modulators, activators or inhibitors, of these channels to correct any TREK-1-related dysfunctions. Despites a number of studies and many molecule screenings, only few putative new drugs were identified. The activators belonging to the ML and BL series ...
Source: Frontiers in Pharmacology - April 10, 2019 Category: Drugs & Pharmacology Source Type: research

Measuring Ambulation, Motor, and Behavioral Outcomes with Poststroke Fluoxetine in Tanzania: The Phase II MAMBO Trial
Am J Trop Med Hyg. 2021 Dec 6:tpmd210653. doi: 10.4269/ajtmh.21-0653. Online ahead of print.ABSTRACTWe test the safety of fluoxetine postischemic stroke in sub-Saharan Africa. Adults with acute ischemic stroke, seen <14 days since new-onset motor deficits, were enrolled from November 2019 to October 2020 in a single-arm, open-label phase II trial of daily fluoxetine 20 mg for 90 days at Muhimbili National Hospital, Dar es Salaam, Tanzania. The primary outcome was safety with secondary outcomes of medication adherence and tolerability. About 34 patients were enrolled (11 were female; mean age 52.2 years, 65% < 60 year...
Source: The American Journal of Tropical Medicine and Hygiene - December 6, 2021 Category: Tropical Medicine Authors: Farrah Mateen Emmanuel Massawe Notburga Mworia Seif Ismail Dylan Rice Andre Vogel Boniface Kapina Novath Mukyanuzi Deus Buma Jef Gluckstein Michael Wasserman Susan Fasoli Faraja Chiwanga Kigocha Okeng'o Source Type: research

Pages: 1  2